Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily supplement boost your Cells' energy? new study seeks answers

NCT ID NCT07428889

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This pilot trial is testing whether a proprietary nutritional supplement can increase levels of NAD+, a molecule important for cellular energy and aging, in healthy adults aged 45 to 65. Participants will take either the supplement or a placebo daily for 60 days. The study aims to measure changes in NAD+ and related markers, as well as subjective feelings of cognitive function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
proprietary nutritional supplement containing nicotinamide metabolites and plant extracts
What this could lead to
If it works, this could point toward a supplement that supports cellular energy and healthy aging in adults.
What could go wrong
This is a very small, early pilot study in healthy people, so results may not apply to the general population or lead to any proven health benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Feb 2026

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females, ≥45 to ≤65 years of age 2. BMI ≥18.5 and \<30.0 kg/m2 3. Ambulatory and currently free of injury or other physical impairment that hinders mobility. 4. Willing to use personal smart phone with operating system (Android version 12.0 or newer; iOS version 16 or newer). 5. Willingness to maintain current skin care regimen and avoid any skin-related medical procedures. 6. Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator. Exclusion Criteria: 1. Is currently following, or planning to be on, a weight loss regimen. 2. Weight loss or gain \>4.5 kg. 3. History of gastrointestinal surgery for weight reducing purposes. 4. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator. 5. History of neurologic disorder that could produce cognitive deterioration. 6. History of bouts of delirium, confusion, repeated minor head injury or a single injury. 7. History of unconventional sleep patterns or a diagnosed sleep disorder. 8. History of any infective or inflammatory brain disease. 9. Use of tobacco/nicotine products. 10. Use of hemp/marijuana products. 11. Unstable use of any prescription medication. 12. Unstable use (initiation or change in dose) of hormonal contraceptives or therapy. 13. Use of any dietary supplements (orally or infused), other than a conventional once daily multi-vitamin. 14. Use of medication(s) or dietary supplement(s) known to affect absorption. 15. Recent history of or strong potential for alcohol or substance abuse. 16. Exposed to any non-registered drug product. 17. A score of \<7 on the Vein Access Scale Assessment. 18. History or presence, on the basis of the medical history or screening labs, of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, gastrointestinal, biliary, pancreatic, or neurological disorders. 19. Uncontrolled hypertension. 20. Known allergy to any ingredients contained in the study product. 21. Any signs or symptoms of active infection of clinical relevance. 22. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. 23. History of any major trauma or major surgical event. 24. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use of sex hormones for contraception. 25. An employee or representative who has a financial interest in Sponsor organization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Biofortis Clinical Research

    Addison, Illinois, 60101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.